Saturday, July 2, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study identified multiple siRNAs spanning the SARS-CoV-2 genome with potent antiviral activity

by Medical Finance
in Coronavirus
Study: Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2. Image Credit: Naty.M/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

A recent study posted to the bioRxiv* preprint server demonstrated that RNA interference (RNAi) could prophylactically protect against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

Study: Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2. Image Credit: Naty.M/Shutterstock
Study: Robust and durable prophylactic protection conferred by RNA interference in preclinical models of SARS-CoV-2. Image Credit: Naty.M/Shutterstock

Background

Coronavirus disease 2019 (COVID-19) vaccines have been developed at an unprecedented pace; nonetheless, challenges in global supply, adherence, and the high viral transmission have contributed to the appearance of novel SARS-CoV-2 variants resulting in continual COVID-19 waves. Hence, there is a pressing need to develop novel antiviral tools/therapies to curb the spread of SARS-CoV-2 and enhance vaccination efforts.

The study and findings

In the present study, researchers showed that small-interfering RNAs (siRNAs) conjugated with 2’-O-palmityl (C16) confer prophylactic protection against SARS-CoV-2. The authors screened conserved genomic sequences of SARS-CoV-2, SARS-CoV, and the Middle East respiratory syndrome CoV (MERS-CoV) viruses. More than 1500 conserved sites were identified between SARS-CoV and SARS-CoV-2 genomes and nine sequences between MERS-CoV and SARS-CoV-2. About 349 RNAi target sequences were selected, and siRNAs corresponding to these sites were developed as conjugates of C16.

In vitro activity was assessed by transfection of dual-luciferase reporters. The target sites on the plus-strand of SARS-CoV-2 were introduced into the 3′ untranslated region of Renilla luciferase as concatemers, with firefly luciferase serving as the control. Ninety-one siRNAs were identified with this assay, and the most effective siRNAs were evaluated in vitro in a live virus infection assay.

The researchers transfected Vero E6 cells with siRNAs before SARS-CoV-2 infection, and viral quantification was done using quantitative reverse transcription polymerase chain reaction. (RT-qPCR). The live virus assay detected 23 siRNAs with more than 2-log reduction of viral RNA at 10nm concentration and four siRNAs with > 3-log reduction at 0.1nm (lowest concentration). No siRNA targeting the minus strand of SARS-CoV-2 RNA demonstrated activity.

Next, the two leading siRNA candidates (COV-siRNA1 and COV-siRNA2) targeting the ORF1ab were further assessed using SARS-CoV-2 N protein immunofluorescence assay. These siRNAs demonstrated potent antiviral activity in a dose-dependent manner. The intracellular N protein was undetectable when the candidate siRNAs were used alone or in combination at 10 nm concentration.

Half-maximal effective concentration (EC50) for COV-siRNA1 was 42pm and 86pm for COV-siRNA2. Drug resistance barriers for these siRNAs were determined by passaging the virus five times with COV-siRNA1 alone or both siRNAs at 5x, 10x, and 20x EC50. Escape mutants of the virus appeared with single siRNA treatment. Still, combination treatment presented a barrier to the emergence of escape mutants, indicating that combining two siRNAs targeting the conserved sites is essential to create a barrier to SARS-CoV-2 escape.

Further, the siRNA binding sites in the SARS-CoV-2 genome were deep-sequenced to understand the decreased susceptibility of single siRNA treatment. Point mutations were observed in the binding site of COV-siRNA1 due to serial passaging and not in that of the COV-siRNA2. Mostly, these mutations emerged as triple thymine mutation (TTM) at 6 – 8 antisense nucleotides (nt. 6 – 8), and in higher passages, two other mutations appeared at nt. 10 and nt. 11. The mutations were non-synonymous and synonymous base substitutions; contrastingly, no mutations were observed with the combination treatment at any siRNA binding sites.

The COV-siRNA1 and CoV-siRNA2 target sequences across publicly available 4386 SARS-CoV-2 genomes were evaluated in silico to determine if any mutations appeared at the target sites. The authors observed no mutations at the target sites of COV-siRNA 1 and 2, indicating that these loci have remained conserved without any significant variation, including in the SARS-CoV-2 variants.

Lastly, the efficacy of siRNA combination treatment was investigated in vivo in Syrian hamsters. The two siRNAs were administered seven days before infection, and luciferase-targeting siRNA was the control. SARS-CoV-2 was inoculated prophylactically at day 0. siRNA treatment resulted in dose-dependent protection of hamsters from weight loss.

Additionally, hamsters were separately treated with two siRNAs one day before infection. These animals lost weight at the same rate as the control group due to the delayed onset of the mechanism. Hamsters treated with siRNAs 30 days before infection showed similar results consistent with animals treated seven days before infection. Moreover, double siRNA treatment reduced viral genomic and subgenomic RNA in the lung tissues.

Conclusions

The present study identified several siRNAs with binding sites spanning the entire SARS-CoV-2 genome and observed that the combination of CoV-siRNA1 and CoV-siRNA2 targets the conserved sequences within ORF1ab. This indicated that the conservation of those sites was critical for viral fitness. The preclinical models demonstrated promising results and warrant further clinical research. Overall, the present study’s findings suggest that the combination siRNA treatment could be crucial in mitigating COVID-19 and might serve as potential prophylaxis against severe disease.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Association of SARS-CoV-2 Infection with Serious Maternal Morbidity and Mortality From Obstetric Complications. Image Credit: milkumistock / Shutterstock.com

The serious risks COVID-19 may pose during pregnancy

by Medical Finance
July 2, 2022
0

In a recent JAMA study, researchers report on the potential for serious maternal illness or death during or following a pregnancy...

Study: BNT162b2 vaccine boosts neutralizing antibodies to ancestral SARS-CoV-2 & Omicron variant in adults received 2-dose inactivated vaccine. Image Credit: Tamer Adel Soliman/Shutterstock

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

by Medical Finance
July 2, 2022
0

The ongoing coronavirus disease 2019 (COVID-19) pandemic has severely disrupted the world in terms of the disease burden and...

Study: Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants. Image Credit: Tatiana Shepeleva/Shutterstock

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

by Medical Finance
July 2, 2022
0

The rapid outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide has resulted in the coronavirus disease...

Study: Humoral and cellular immune memory to four COVID-19 vaccines. Image Credit: Telnov Oleksii/Shutterstock

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

by Medical Finance
July 2, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers evaluated the humoral and cellular immune memory induced by...

Study: High neutralizing antibody levels against SARS-CoV-2 Omicron after UB-612 booster vaccination. Image Credit: natatravel/Shutterstock

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

by Medical Finance
July 2, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers evaluated the effectiveness of a novel vaccine candidate UB-612...

Study: Variation of total anti-SARS-CoV-2 antibodies after primary BNT162b2 vaccination and homologous booster. Image Credit: BaLL LunLa/Shutterstock

Study investigates anti-SARS-CoV-2 antibody levels following Pfizer vaccine primary and booster regimens

by Medical Finance
July 2, 2022
0

A recent article posted to the Research Square* preprint server presented the differences among total anti-severe acute respiratory syndrome coronavirus 2...

Next Post
Study: Broadly-recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles. Image Credit: CI Photos/Shutterstock

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

Study opens the door to a new approach to attacking herpesviruses

Study opens the door to a new approach to attacking herpesviruses

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Binding behavior of spike protein and receptor binding domain of the SARS-CoV-2 virus at different environmental conditions. Image Credit: Andrii Vodolazhskyi/Shutterstock
    The effect of different environmental conditions on the binding behavior of the S protein and RBD of SARS-CoV-2
  • Study: Risk of myocarditis and pericarditis following COVID-19 vaccination in England and Wales. Image Credit: MattLphotography/Shutterstock
    Incidence of myocarditis and pericarditis following COVID-19 vaccination
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply